AMD

By identifying progressive GA earlier, primary eye care providers can make timely referrals and save patients’ visual function.

Understanding the latest innovative technologies.

Comanagement is a key component for treatment of disease.

The new smart glasses utilize artificial intelligence to visually assist those with age-related macular degeneration and other retinal disorders causing vision loss.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

A new analysis by researchers at the National Institutes of Health shows the benefit of taking AREDS2 formula in late AMD.

The 2-year Phase III data demonstrates Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

The company also submitted a marketing authorization application with the European Medicines Agency.

Notal Vision’s device was given to 15 patients to track changes in their neovascular age-related macular degeneration for the study.

Apellis will seek re-examination from the CHMP following the opinion, according to a news release.

The company expects enrollment of the GAZE phase 1, open-label clinical trial, to begin in the second half of 2024.

Respecting the clinical importance of the pachychoroid spectrum is vital when analyzing OCT scans.

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

Researchers examined data of more than 200,000 people, 121,523 of which had no history of AMD.

The biotechnology company is developing the first protein-based artificial retina for patients with retinitis pigmentosa and age-related macular degeneration.

The COAST and ShORe trials have a total of 1984 patients enrolled for the treatment of wet age-related macular degeneration.

The study evaluated the effects of long-term, low-dose aspirin administration in over 3000 older adults.

Aflibercept-jbvf and aflibercept-yszy are the first interchangeable biosimilars to aflibercept 2 mg that have been approved in the US.

The SCANLY Home OCT device allows physicians to monitor patients’ wet age-related macular degeneration in between visits through a health cloud portal.

The clinical-stage biopharmaceutical company has enrolled 15 participants in its study to assess the safety and tolerability of ACT107 in 3 dose strengths.

Conditionally accepted by the FDA as EYO-1901, DURAVYU is a tyrosine kinase inhibitor intended to improve signs and symptoms of non-proliferative diabetic retinopathy in the PAVIA trial.

The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene, the company stated in a news release.

The AI-powered model works to detect early signs of glaucoma and makes iHealthScreen the first company to receive 2 US patents for AMD and glaucoma screening devices.

The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.

The South Korean study found that those with age-related macular degeneration may be more at risk of developing some cancers, like renal and thyroid.

New treatments for geographic atrophy coming down the pike has the potential to change eye care providers' approach to identifying and managing the disease.

The clinical-stage biopharmaceutical company is running 2 Phase 3 clinical trials, COAST and ShORe, to assess the efficacy and safety of using combinations of certain drugs to treat wet age-related macular degeneration.

AREDS2 supplementation and close monitoring of gut microbiota may help patients at risk for vision loss.

The study further defined the relationship between delayed rod-mediated dark adaptation and the status of outer retinal bands on optical coherence tomography.